Rain Oncology Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
63
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$50M
Rain Oncology General Information
Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Contact Information
Website
www.rainoncology.com(Operating Subsidiary)
Corporate Office
- 8000 Jarvis Avenue
- Suite 204
- Newark, CA 94560
- United States
Corporate Office
- 8000 Jarvis Avenue
- Suite 204
- Newark, CA 94560
- United States
Rain Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 26-Jan-2024 | $50M | Completed | Generating Revenue | ||
| 5. PIPE | 08-Nov-2022 | Completed | Generating Revenue | |||
| 4. IPO | 23-Apr-2021 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series B) | 12-Sep-2020 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 02-May-2018 | $18.4M | $19.4M | Completed | Startup | |
| 1. Seed Round | 13-Dec-2017 | $1M | $1M | Completed | Startup |
Rain Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Rain Oncology Comparisons
Industry
Financing
Details
Rain Oncology Competitors (9)
One of Rain Oncology’s 9 competitors is PMV Pharma, a Formerly VC-backed company based in Princeton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PMV Pharma | Formerly VC-backed | Princeton, NJ | ||||
| Senhwa Biosciences | Formerly VC-backed | New Taipei City, Taiwan | ||||
| Kartos Therapeutics | Formerly VC-backed | Redwood City, CA | ||||
| Erasca | Formerly VC-backed | San Diego, CA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
Rain Oncology Patents
Rain Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021127456-A1 | Methods of inhibiting epidermal growth factor receptor proteins | Inactive | 19-Dec-2019 | ||
| WO-2020205627-A1 | Use of biomarker in cancer therapy | Inactive | 29-Mar-2019 | ||
| WO-2020102304-A1 | Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same | Inactive | 13-Nov-2018 | ||
| AU-2019338185-A1 | Compounds, compositions and methods for treating or preventing her-driven cancers | Inactive | 04-Sep-2018 | ||
| CA-3110658-A1 | Compounds, compositions and methods for treating or preventing her-driven cancers | Inactive | 04-Sep-2018 | C12Q1/6886 |
Rain Oncology Signals
Rain Oncology Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | ||
| Auckland UniServices | Corporate Venture Capital | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Boxer Capital | Corporate Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority |
Rain Oncology ESG
Risk Overview
Risk Rating
Updated September, 30, 2023
27.53 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
Rain Oncology FAQs
-
When was Rain Oncology founded?
Rain Oncology was founded in 2017.
-
Where is Rain Oncology headquartered?
Rain Oncology is headquartered in Newark, CA.
-
What is the size of Rain Oncology?
Rain Oncology has 63 total employees.
-
What industry is Rain Oncology in?
Rain Oncology’s primary industry is Drug Delivery.
-
Is Rain Oncology a private or public company?
Rain Oncology is a Private company.
-
What is the current valuation of Rain Oncology?
The current valuation of Rain Oncology is .
-
What is Rain Oncology’s current revenue?
The current revenue for Rain Oncology is .
-
How much funding has Rain Oncology raised over time?
Rain Oncology has raised $274M.
-
Who are Rain Oncology’s investors?
Adage Capital Management, Auckland UniServices, BVF Partners, Boxer Capital, and Cormorant Asset Management are 5 of 10 investors who have invested in Rain Oncology.
-
Who are Rain Oncology’s competitors?
PMV Pharma, Senhwa Biosciences, Kartos Therapeutics, Erasca, and Rein Therapeutics are some of the 9 competitors of Rain Oncology.
-
When was Rain Oncology acquired?
Rain Oncology was acquired on 26-Jan-2024.
-
Who acquired Rain Oncology?
Rain Oncology was acquired by Pathos AI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process